Skybiotech Healthcare Ltd
Skybiotech Healthcare Ltd (SKYBIOTECH) last reported results for the quarter ended Jun 2026, with sales of ₹0.49 crore and net profit of ₹-0.57 crore. The stock last traded at ₹117, a market capitalisation of ₹22.4 crore. Over the past 52 weeks the stock has ranged between ₹114 and ₹218. Figures are as of 9 Oct 2026 and are not real time.
Skybiotech Healthcare Ltd share price and key metrics
- Current price
- ₹117
- Market cap
- ₹22.4 cr
- Book value
- ₹41.8
- ROE
- -13.2%
- ROCE
- -9.32%
- Dividend yield
- 0.00%
- 52w high / low
- 218/114
Metrics as of 9 Oct 2026. Not real time.
Track Skybiotech Healthcare Ltd
Cruxal reads every Skybiotech Healthcare Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Skybiotech Healthcare Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -31%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 5%
- 10 Years
- -2%
- 5 Years
- 30%
- 3 Years
- 1%
- 1 Year
- -41%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- -13%
Skybiotech Healthcare Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.49 cr, down 79.5% from ₹2.39 cr a year earlier. Net profit was ₹-0.57 cr, down 2750.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.6 | 2.52 | 1.02 | 2.39 | 1.92 | 0.96 | 1.83 | 0.49 |
| Expenses | 1.58 | 2.83 | 2.11 | 2.31 | 2.15 | 1.41 | 2.71 | 1.02 |
| Operating profit | 0.02 | -0.31 | -1.09 | 0.08 | -0.23 | -0.45 | -0.88 | -0.53 |
| OPM % | 1.25% | -12.30% | -106.86% | 3.35% | -11.98% | -46.88% | -48.09% | -108.16% |
| Other income | 0.04 | 0.15 | -0.18 | 0.03 | 0.04 | 0.08 | 0.15 | 0.06 |
| Interest | 0.13 | 0.11 | -0.23 | 0.01 | 0 | 0 | 0 | 0 |
| Depreciation | 0.13 | 0.14 | 0.15 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 |
| Profit before tax | -0.2 | -0.41 | -1.19 | -0.02 | -0.31 | -0.49 | -0.85 | -0.58 |
| Tax % | 30.00% | -4.88% | -8.40% | 0.00% | 0.00% | 0.00% | -64.71% | 0.00% |
| Net profit | -0.25 | -0.39 | -1.08 | -0.02 | -0.31 | -0.48 | -0.3 | -0.57 |
| EPS (₹) | -1.31 | -2.04 | -5.64 | -0.10 | -1.62 | -2.51 | -1.57 | -2.98 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Skybiotech Healthcare Ltd annual results
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 0 | 6.96 | 6.99 | 5.2 |
| Operating profit | -0.12 | -2.25 | -1.48 | -2.09 |
| OPM % | — | -32.33% | -21.17% | -40.19% |
| Net profit | 1.54 | -2.37 | -1.12 | -1.66 |
| EPS (₹) | 8.04 | -12.38 | -5.85 | -8.68 |
TTM is the trailing twelve months to the most recent quarter.
Skybiotech Healthcare Ltd balance sheet
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 1.92 | 1.92 |
| Reserves | 7.07 | 6.08 |
| Borrowings | 7.20 | 8.42 |
| Other liabilities | 3.91 | 3.02 |
| Total liabilities | 20.10 | 19.44 |
| Fixed assets | 12.03 | 11.55 |
| CWIP | 0.00 | 0.00 |
| Investments | 2.46 | 2.24 |
| Other assets | 5.61 | 5.65 |
| Total assets | 20.10 | 19.44 |
As reported by the company. Total assets equal total liabilities by construction.
Skybiotech Healthcare Ltd cash flow
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operations | -1.04 | -1.52 |
| Cash from investing | -9.63 | 0.02 |
| Cash from financing | 1.24 | 1.17 |
| Net cash flow | -9.43 | -0.33 |
| Free cash flow | -1.37 | -1.52 |
| CFO / operating profit | 46% | 103% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Skybiotech Healthcare Ltd operating ratios
| Per year | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | — | -9.32% |
| Debtor days | 22.03 | 57.96 |
| Inventory days | — | 356.10 |
| Days payable | — | 378.35 |
| Cash conversion cycle | 22.03 | 35.71 |
| Working capital days | -27.27 | -1.57 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Skybiotech Healthcare Ltd shareholding pattern
Promoters held 63.48% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 62.71% | 62.71% | 63.48% | 63.48% | 63.48% | 63.48% | 63.48% | 63.48% |
| Public | 37.29% | 37.28% | 36.53% | 36.52% | 36.53% | 36.52% | 36.53% | 36.53% |
| No. of shareholders | 361 | 660 | 597 | 664 | 615 | 620 | 610 | 632 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Skybiotech Healthcare Ltd corporate filings
- Skybiotech Healthcare Limited's recent AGM voting results show overwhelming approval for key resolutions, with nearly 100% support for financial and strategic decisions, indicating strong shareholder backing despite ongoing financial losses.AGM/EGMmedium impact
Cruxal's analysis: Skybiotech Healthcare Limited, a small-cap company with a market cap of approximately ₹22…
Read the full analysis - Intimation of Trading Window closure to declared financial results for the Quarter ended on 30th September, 2026Insider Trading / SASTlow impact
- Skybiotech Healthcare Limited holds 43rd AGM; no new financial disclosures or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: Skybiotech Healthcare Limited (formerly Kapil Cotex Limited) conducted its 43rd Annual…
Read the full analysis - Skybiotech Healthcare Limited's AGM outcome confirms approval of FY2025-26 financial statements amid ongoing lossesAGM/EGMlow impact
Cruxal's analysis: Skybiotech Healthcare Limited held its 43rd AGM on 30th September 2026, where the…
Read the full analysis - Skybiotech Healthcare Limited Announces 43rd Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: Skybiotech Healthcare Limited has issued a formal notice for its 43rd Annual General…
Read the full analysis - Skybiotech Healthcare Ltd submits Annual Report for FY 2025-2026Otherslow impact
Cruxal's analysis: Skybiotech Healthcare Ltd has filed its Annual Report for the financial year 2025-2026 as…
Read the full analysis - Skybiotech Healthcare Limited Reports Mixed Quarterly Results with Standalone Profitability and Consolidated LossesBoard Meetingmedium impact
Cruxal's analysis: Skybiotech Healthcare Limited (formerly Kapil Cotex Ltd) reported standalone net profit…
Read the full analysis - Skybiotech Healthcare Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Skybiotech Healthcare Limited has formally intimated the BSE regarding a Board Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.